Antibacterial medicines in clinical pipelines decline, report says

I’m excited to share the recent FDA approval of Jascayd (nerandomilast), the first new oral treatment for idiopathic pulmonary fibrosis (IPF) in over a decade. IPF is a serious, progressive lung disease characterized by scarring of lung tissue, which significantly impairs breathing and quality of life. Jascayd works by specifically inhibiting enzymes responsible for the fibrotic process in the lungs, potentially slowing disease progression and improving patient outcomes. This novel antifibrotic therapy provides a much-needed treatment option for patients with limited alternatives. Increasing awareness about Jascayd is vital to encourage early diagnosis and timely treatment intervention in IPF, ultimately impacting patients’ lives positively. I encourage healthcare professionals and the public alike to stay informed about this breakthrough medication. Here is an official image and detailed information about Jascayd (nerandomilast), the recently approved drug for idiopathic pulmonary fibrosis (IPF): FDA Approval News: FDA Approves Jascayd Manufacturer Site: Jascayd by Boehringer Ingelheim #Pharmacy #DrugUpdate #IdiopathicPulmonaryFibrosis #FDAApproval #Jascayd #LungHealth #PharmaceuticalSciences #HealthcareInnovation

Shortages of critical medicines, from antibiotics to oncology, are raising growing concern across Europe and beyond. In the past year, we supplied voluntarily more than two million units of critical medicines for Pan-EU export and helped resolve over 500 external caused national shortages in 26 countries (read more: https://lnkd.in/dZ6pZTKr) By reallocating stocks we resolved 385 shortages in the first eight months of 2025 – a 22% increase compared to the same period in 2024. By supporting medicines to where patients needed them most, often in countries where no other company was present, we made a real difference. It’s about more than numbers – it’s about addressing patient needs and supporting health systems, when it matters. #TevaPharm #Tevapharmaceuticals #TevaOTC #PatientsFirst #HealthcareResilience #CriticalMedicines #Medicines

🔬💊 Clinical Trial Phases – Building Trust in Medicines We Use Daily Every medicine we take—whether it’s for a headache, diabetes, or heart disease—has gone through a long and rigorous process called clinical trials before reaching us. These trials ensure that what we consume is safe, effective, and trustworthy. 🌿 Phases of Clinical Trials: 1️⃣ Preclinical Research (Before Human Trials) ✔️ Testing on cells & animals ✔️ Checks safety and biological activity 2️⃣ Phase I (Safety First) 👩⚕️ Small group of healthy volunteers 👀 Evaluates safety, dosage, and side effects 3️⃣ Phase II (Does it Work?) 🧑🤝🧑 Hundreds of patients 🔎 Tests effectiveness & further safety checks 4️⃣ Phase III (Large-Scale Proof) 🌍 Thousands of patients across multiple locations ⚖️ Confirms effectiveness, compares with standard treatments, monitors side effects 5️⃣ Phase IV (Post-Marketing Surveillance) 🏥 After approval, medicine is tracked in real-world use 🔐 Ensures long-term safety and effectiveness 💡 Why it matters in daily life? 👉 The painkiller you take, the insulin you inject, or the antibiotics you rely on—all are available today because of these clinical trial phases. 👉 They protect us from unsafe or ineffective treatments. 👉 They build trust in modern medicine, ensuring better health outcomes for everyone. 🌍 Let’s appreciate the rigorous journey behind every pill, injection, or vaccine—it’s science working silently for our health every day. #ClinicalResearch #HealthcareAwareness #ClinicalTrials #Pharmaceuticals #SafetyFirst

💡 𝐍𝐞𝐰 𝐀𝐏𝐌𝐌𝐀 𝐅𝐞𝐚𝐭𝐮𝐫𝐞 Rare disease patients in England may miss out on Astellas Pharma's Betmiga.    Discover why the company chose not to submit the drug to England's health technology assessment (HTA) body NICE - National Institute for Health and Care Excellence 👉 Read the full story here: https://lnkd.in/eF4mPSC6 #gynaecology #nice #pharma #marketaccess #apmmarketaccess

🌐 Same Molecule, Different Decision: Why Mounjaro and Zepbound Face Different Prior Authorization Outcomes 💊 In the world of pharmacy billing and prior authorization, not all identical molecules are treated equally. 👉 Tirzepatide — the active ingredient in both Mounjaro and Zepbound — is a perfect example. Though chemically identical, their FDA labeling, clinical evidence, and therapeutic indications draw a clear line in coverage policies: Mounjaro → Approved for Type 2 Diabetes Mellitus (supported by SURPASS trials). Zepbound → Approved for Chronic Weight Management (supported by SURMOUNT trials). 🔍 Why coverage differs: Payers approve drugs based on labeled indication, not molecule. Separate NDAs mean separate formulary tiers and reimbursement pathways. Off-label prescribing (e.g., using Mounjaro for obesity) is legal but often denied unless strong guideline support exists. Formulary design, step therapy, and cost containment further shape the outcome. 💬 In short: > “The same molecule can pass in one prior authorization and fail in another — not because of chemistry, but because of policy.” 📄 Key takeaway for PA teams: ✅ Match the diagnosis to the label. ✅ Cite the correct clinical trial (SURPASS vs SURMOUNT). ✅ Attach supporting documentation (BMI, A1c, prior therapy). ✅ Reference the FDA indication in every justification. ⚖️ Coverage = Compliance + Correct Labeling 💡 “Right Drug. Right Indication. Right Evidence.” #PharmacyBilling #PriorAuthorization #Zepbound #Mounjaro #FDAApproval #PharmacistInsights #MedicalBilling #HealthcareCompliance #PharmaPolicy #DrugUtilization #EvidencedBasedPractice

The Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Sanofi's medicine for #ChronicSpontaneousUrticaria (CSU) in certain adults and adolescents. CSU is an inflammatory skin disease associated with sudden and debilitating hives and recurring itch. Learn more about the news:http://spkl.io/6045Ardav

Our latest blog by Markus Gores and Emily Clark on long-acting parenterals offers deep insights into the latest advancements in drug delivery systems. Learn how these innovations are improving patient compliance and therapeutic outcomes, read now https://bit.ly/3WaQM6s #AnalyticsLinkEcosystem #PharmaDeals #ArkPatentIntelligence

GLP-1s are reshaping obesity and diabetes care ⬇️ What started with diabetes drugs (Ozempic, Mounjaro) is now a global shift in how we treat obesity and cardiometabolic disease. Inside the infographic: 🔹 The scale of the GLP-1 boom — $100B+ potential by 2030 🔹 Why payers are divided, and how coverage is evolving 🔹 The next wave: oral GLP-1s and multi-agonists The takeaway: GLP-1s are no longer a niche story — they’re transforming chronic disease care, access debates, and pharma strategy all at once. View the visual breakdown to see where the market is heading. #Pharma #Biotech #GLP1 #ObesityCare #Diabetes #DrugDevelopment

For better or worse, methods for assessing the value of therapies haven’t fundamentally changed for many years. But as reimbursement environments become ever more constrained, assessment mechanisms that were never designed to adequately account for different evidence generation parameters for rare diseases are coming under pressure. And HTA valuation systems that have worked relatively well in the past simply don’t appropriately reflect the impact of many rare diseases, or the value new therapies bring. More than perhaps any other area, missteps in strategy and evidence generation in rare diseases have negative consequences for access, and therefore for patients. And access negotiations are complicated by the need for parallel policy and methods changes that are well beyond the influence of individual pharmaceutical companies. As we turn a lens on rare diseases in the lead up to #WODC, our latest insights article explores 6 key challenges associated with rare disease reimbursement, and potential strategies for overcoming them 👇 https://cstu.io/34586e #RareDiseases #MarketAccess #HTA #FindYourRedThread

💊 𝐅𝐃𝐀-𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐝… 𝐓𝐡𝐞𝐧 𝐖𝐢𝐭𝐡𝐝𝐫𝐚𝐰𝐧! Did you know that even FDA-approved drugs can be withdrawn from the market years after approval? From Vioxx to Ranitidine, history shows us that approval does not always 𝐠𝐮𝐚𝐫𝐚𝐧𝐭𝐞𝐞 𝐥𝐨𝐧𝐠-𝐭𝐞𝐫𝐦 𝐬𝐚𝐟𝐞𝐭𝐲. • 𝐕𝐢𝐨𝐱𝐱 (𝐑𝐨𝐟𝐞𝐜𝐨𝐱𝐢𝐛) – Approved 1999 for pain relief → Withdrawn 2004 | Reason: heart attacks & strokes • 𝐑𝐚𝐧𝐢𝐭𝐢𝐝𝐢𝐧𝐞 (𝐙𝐚𝐧𝐭𝐚𝐜) – Approved 1983 for GERD & ulcers → Withdrawn 2020 | Reason: probable carcinogen (NDMA) • 𝐋𝐨𝐫𝐜𝐚𝐬𝐞𝐫𝐢𝐧 (𝐁𝐞𝐥𝐯𝐢𝐪) – Approved 2012 for weight management → Withdrawn 2020 | Reason: increased cancer risk • 𝐅𝐞𝐧-𝐏𝐡𝐞𝐧 (𝐅𝐞𝐧𝐟𝐥𝐮𝐫𝐚𝐦𝐢𝐧𝐞/𝐏𝐡𝐞𝐧𝐭𝐞𝐫𝐦𝐢𝐧𝐞) – Approved 1996 for obesity → Withdrawn 1997 | Reason: heart valve damage & pulmonary hypertension. 𝐚𝐧𝐝 𝐦𝐚𝐧𝐲 𝐦𝐨𝐫𝐞..... 💡 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬: 👉 Continuous post-marketing surveillance is crucial. 👉 Healthcare professionals and patients must stay vigilant even with approved medications. 👉 Regulatory systems must evolve to detect long-term adverse effects earlier. Drug development is not just about getting approval, it’s about ensuring long-term safety and trust. #DrugSafety #PharmaInsights #FDA #PatientSafety #Healthcare #Pharmaceuticals